Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #2
Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #2
$599.00
A US key opinion leader (KOL) discusses the approach to treating major depressive disorder as well as the most pressing unmet needs in the market, and provides insights into key late-phase pipeline drugs for major depressive disorder.
Publisher: Biomedtracker
- Highlights
- Description
Highlights
- “The biggest unmet needs are treating patients with refractory depression, and severe suicidal ideation, because those patients need something that is going to act quickly. Some of them start to give up after a point because they are not responding.”
- “There is never going to be the perfect drug for every patient, and I think that it [brexanolone] is going to get a huge market share when it comes out, very good trials, very good data, a lot of time and effort put in to the drug.”
Drug Coverage
- Abilify
- ALKS 5461
- BuSpar
- Cymbalta
- Esketamine
- Fetzima
- ketamine
- Lexapro
- Pristiq
- Prozac
- Rapastinel
- Rexulti
- SAGE-217
- Seroquel
- Travivo
- Trintellix
- Viibryd
- Vraylar
- Zulresso
Overview
A US key opinion leader (KOL) discusses the approach to treating major depressive disorder as well as the most pressing unmet needs in the market, and provides insights into key late-phase pipeline drugs for major depressive disorder.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Synagis 
Sign up to the